- Home
- INFY vs TEVA Comparison
INFY vs TEVA Comparison
Compare INFY & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INFY | TEVA |
|---|---|---|
| Founded | 1981 | 1901 |
| Country | India | Israel |
| Employees | N/A | 32842 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.5B | 39.9B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | INFY | TEVA |
|---|---|---|
| Price | $12.57 | $34.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $14.60 | ★ $38.63 |
| AVG Volume (30 Days) | ★ 17.2M | 4.9M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.87 | N/A |
| Revenue Next Year | $6.67 | $2.97 |
| P/E Ratio | ★ $19.11 | $28.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.56 | $14.99 |
| 52 Week High | $30.00 | $37.35 |
Technical Indicators
Market Signals| Indicator | INFY | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 52.60 |
| Support Level | $11.56 | $33.61 |
| Resistance Level | $13.04 | $35.32 |
| Average True Range (ATR) | 0.51 | 0.93 |
| MACD | 0.07 | -0.25 |
| Stochastic Oscillator | 43.85 | 66.78 |
Price Performance
Historical ComparisonAbout INFY Infosys Limited
Infosys is an IT services provider based in Bengaluru, India, with offices in more than 50 countries. The company leverages its offshore outsourcing model to serve clients across different industries, such as financial services and manufacturing. Infosys' IT services offerings include consulting, digital transformation, and business process outsourcing.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.